Abstract The effect of TP53 alterations on childhood B-cell acute lymphoblastic leukemia (B-ALL) remains unclear. To investigate the impact of TP53 deletion (TP53del) and TP53 mutation (TP53mut) on prognosis, this post-hoc study used fluorescence in situ hybridization test to detect TP53del in 914 newly diagnosed B-ALL children from a prospective Chinese Children’s Cancer Group ALL-2015 cohort. Targeted gene sequencing was used to identify TP53mut in 345 out of the 914 patients. TP53del was detected in 4.4% of cases. The frequency of hypodiploidy was higher in TP53del subgroup (7.5% vs. 0.5%, P = 0.002), but patients with TP53del were less likely to have other recurrent genetic abnormalities, including BCR::ABL1, ETV6::RUNX1, TCF3::PBX1 and MLL rearrangement. Univariable and multivariable analyses indicated that TP53del was an independent risk factor for overall and disease-free survival. Furthermore, stratification analysis revealed that TP53del was associated with adverse outcomes in patients with positive MRD after induction (0.0% vs. 58.2%, P < 0.001), suggesting an MRD-dependent pattern. But TP53mut was not associated with poor survival (79.2% vs. 85.3%, P = 0.317). In summary, TP53del may serve as a predictor for poor prognosis in pediatric B-ALL. Especially children in intermediate-risk group with positive MRD and TP53del may deserve more aggressive treatment.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: